To the Editor.
—We conducted the present analysis to assess the impact of the publication1 of the preliminary analysis of the Concorde Trial2 and its associated publicity3,4 on zidovudine utilization in the province of British Columbia. The distribution of antiretroviral drugs in British Columbia is free of charge through the provincial Centre for Excellence in HIV/AIDS [human immunodeficiency virus/acquired immunodeficiency syndrome]. In order for physicians to prescribe zidovudine, they complete a patient enrollment form that serves as the drug prescription. This application is usually accompanied by a CD4 cell count determination. Individuals infected with HIV are eligible to receive zidovudine from this program if they have at least one CD4 cell count less than 0.50 ×109/L (500/μL). There is no other legal source of zidovudine in the province.A total of 564 new zidovudine requests were received during the first 9 months of 1993. As